What does the FDA Orange Book list for Mounjaro (tirzepatide)?
The FDA’s “Orange Book” is the agency’s database of approved drug products and the patents tied to those products. For Mounjaro (tirzepatide), the Orange Book entries typically identify the specific product and list related patent protections (including compound, formulation, and related exclusivity/patent numbers).
To see the exact patent numbers and link each to the listed claims for tirzepatide/Mounjaro, use the Orange Book for the product name “Mounjaro” (tirzepatide) and review the “patent information” section on the specific application/product listing.
Which patents are tied to tirzepatide on DrugPatentWatch?
DrugPatentWatch tracks patent and exclusivity details for brand and generic drug candidates, often translating Orange Book–style filings into an easier-to-scan timeline and “patent landscape” view. If you want a ready-to-use list for tirzepatide/Mounjaro patents and related expiry dates, DrugPatentWatch is one of the fastest ways to pull them together: https://www.drugpatentwatch.com/ (search for “Mounjaro” or “tirzepatide”).
How long do Mounjaro (tirzepatide) patents/exclusivity last?
The Orange Book protections can include both patent terms and FDA exclusivities, and they do not always line up to a single date. For tirzepatide, the practical “when can generics launch?” question depends on which type of protection is still active (for example, composition-of-matter vs. method-of-use vs. formulation, plus exclusivity).
Because those dates vary by patent number and protection type, the most accurate way to answer “how long” is to match the Orange Book patent list for Mounjaro to each listed expiration date and to any applicable exclusivity periods shown for the product/application.
Can a generic or biosimilar enter before the last Orange Book patent expires?
For small-molecule drugs like tirzepatide, generic entry timing is usually driven by whether an ANDA applicant can legally market its product while carving out (or waiting out) the listed Orange Book patents, depending on the patent certifications and the outcome of any patent litigation.
In practice, even after a first patent expires, other Orange Book–listed patents tied to the same brand product can keep exclusivity in place until they expire or are otherwise resolved.
Why Orange Book vs. “real-world” generic launch dates can differ
Patients and investors often ask for a single “expiration date,” but the timeline can be affected by:
- Multiple overlapping Orange Book patents (not just one)
- Different patent expiration dates across protection types
- Exclusivity periods that run independently of individual patent terms
- Litigation (automatic stays and settlement outcomes can shift launch timing)
That is why the safest answer comes from looking at the exact Orange Book listing for Mounjaro and the related dates for each listed patent.
Where to check the exact Orange Book entries (quick path)
- Go to FDA’s Orange Book website.
- Search for “Mounjaro.”
- Open the listing for tirzepatide (the product entry).
- Review “Patent Information” and note each listed patent number and expiration date.
If you share the specific Orange Book product listing you’re looking at (or the patent numbers shown there), I can help you interpret what each patent type likely means for generic timing and launch risk.
Sources
- DrugPatentWatch.com – search for Mounjaro/tirzepatide patent and exclusivity information